Journal
ONKOLOGIE
Volume 35, Issue 1-2, Pages 35-38Publisher
KARGER
DOI: 10.1159/000336144
Keywords
Oral cyclophosphamide; Solid tumors
Categories
Ask authors/readers for more resources
Background: Cure is rarely achieved in patients with advanced metastatic solid tumors, and quality of life including times without burdening therapies is an important endpoint. Metronomic oral cyclophosphamide (Cy) has been studied before and is a reasonable option. Patients and Methods: 24 patients with a mean age of 64.4 years (range 36-82 years) were studied. 18 patients had breast cancer, 4 prostate cancer, 1 uterine carcinoma, and 1 carcinoma of unknown primary. Results: All patients had advanced disease with a mean of 2 metastatic sites. Cy was given at a mean dosage of 52 mg daily. Time from diagnosis to start of Cy was 108.6 +/- 7.6 months, and from occurrence of metastatic disease to Cy 45.8 +/- 45.6 months. Patients had received a mean of 4.2 +/- 2.1 prior regimens for metastatic disease. The mean time to treatment failure was 6.4 +/- 5.4 months, and mean overall survival was 12.7 +/- 7.3 months. Patients received 2.1 +/- 1.4 further treatments upon progression. Main toxicities were grade 1 and 2 (n = 25); 3 patients had grade 3 nausea, leucopenia, and elevated gamma glutamyl transferase, respectively. Conclusion: Low-dose oral Cy is a reasonable, generally well tolerated, and inexpensive option for patients with advanced solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available